Finance

Beta
Lists
BSX:NYSE
Boston Scientific Corp
$44.33
-2.12%
(-0.96) 1D
$44.74
+0.92% (+0.41)
Pre-market
Closed: Jun 22, 4:00:04 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BSX...
Open
$44.95
High
$45.22
Low
$44.05
Mkt. cap
65.89B
Avg. vol.
21.68M
Volume
5.07K
P/E ratio
18.59
52-wk high
$109.50
52-wk low
$44.05
EPS
$2.38
Beta
0.56
Shares outstanding
1.49B
No. of employees
59K
Open
$44.95
High
$45.22
Low
$44.05
Mkt. cap
65.89B
Avg. vol.
21.68M
Volume
5.07K
P/E ratio
18.59
52-wk high
$109.50
52-wk low
$44.05
EPS
$2.38
Beta
0.56
Shares outstanding
1.49B
No. of employees
59K
News stories
From sources across the web
Profile
Boston Scientific Corporation is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology. The company is known for the development of the Taxus Stent, a drug-eluting stent which is used to open clogged arteries. The company acquired Cameron Health in June 2012 and began to offer a minimally invasive implantable cardioverter-defibrillator called the EMBLEM subcutaneous implantable defibrillator. Over the last 20 years, Boston Scientific has had some high-profile patent infringement cases. It has made extensive payouts, including $1.725 billion to Johnson & Johnson, $85 million to Nevro and $42 million to TissueGen. BSC is headquartered in Marlborough, Massachusetts and incorporated in Delaware. Wikipedia
About Boston Scientific Corp
CEOMichael F. Mahoney
Employees59K
FoundedJun 29, 1979
HeadquartersMarlborough, Massachusetts, United States
SectorMedical device
Websitebostonscientific.com
Analyst Ratings
Based on 25 analysts giving stock ratings to BSX in the past 3 months
Strong Buy
Buy
22
Hold
3
Sell
0
12 month forecast
Based on 25 Wall Street analysts offering 12 month price targets for BSX in the last 3 months.
Highest
Current $44.33
$100.00 (+125.58%)
Average
$76.43 (+72.41%)
Lowest
$55.00 (+24.07%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Josh Jennings
TD Cowen
Buy
Reiterated
$61.00
+37.6%
06/22/2026
Marie Thibault
BTIG
Buy
Reiterated
$65.00
+46.6%
06/15/2026
Matthew O'Brien
Piper Sandler
Buy
Maintained
$65.00
+46.6%
06/12/2026
Travis Steed
Bank of America Securities
Buy
Reiterated
$61.00
+37.6%
06/12/2026
Stephanie Elghazi
Bank of America Securities
Buy
Maintained
$68.00
+53.4%
06/09/2026
Richard Newitter
Truist Financial
Buy
Reiterated
$64.00
+44.4%
06/04/2026
William Plovanic
Canaccord Genuity
Buy
Reiterated
$70.00
+57.9%
06/01/2026
Michael Polark
Wolfe Research
Hold
Downgraded
-
-
05/29/2026
Joanne Wuensch
Citi
Buy
Maintained
$70.00
+57.9%
05/29/2026
Shagun Singh Chadha
RBC Capital
Buy
Maintained
$100.00
+125.6%
05/27/2026
David Roman
Goldman Sachs
Buy
Reiterated
$71.00
+60.2%
05/27/2026
David Rescott
Robert W. Baird
Buy
Maintained
$70.00
+57.9%
05/28/2026
Mike Kratky
Leerink Partners
Buy
Maintained
$74.00
+66.9%
05/28/2026
Larry Biegelsen
Wells Fargo
Hold
Downgraded
$55.00
+24.1%
05/28/2026
Matt Miksic
Barclays
Buy
Maintained
$89.00
+100.8%
05/28/2026
Robbie Marcus
J.P. Morgan
Buy
Maintained
-
-
05/27/2026
Rick Wise
Stifel Nicolaus
Buy
Maintained
$75.00
+69.2%
05/27/2026
Matthew Taylor
Jefferies
Buy
Maintained
$100.00
+125.6%
05/19/2026
Michael Matson
Needham
Buy
Reiterated
$77.00
+73.7%
05/18/2026
Suraj Kalia
Oppenheimer
Buy
Maintained
$90.00
+103%
04/23/2026
David Toung
Argus Research
Buy
Reiterated
$95.00
+114.3%
04/24/2026
Christopher Pasquale
Nephron
Buy
Upgraded
$85.00
+91.7%
04/23/2026
Anthony Petrone
Mizuho Securities
Buy
Maintained
-
-
04/21/2026
Vijay Kumar
Evercore ISI
Buy
Reiterated
$80.00
+80.5%
04/06/2026
Hans Engel
Erste Group
Hold
Reiterated
-
-
04/01/2026
Jayson Bedford
Raymond James
Buy
Maintained
$88.00
+98.5%
03/27/2026
Danielle Antalffy
UBS
Buy
Reiterated
$105.00
+136.9%
03/17/2026
Patrick Wood
Morgan Stanley
Buy
Reiterated
$118.00
+166.2%
03/11/2026
Lee Hambright
Bernstein
Buy
Maintained
$112.00
+152.7%
02/05/2026
Last report
Apr 22, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
$0.80 / $0.79
+1.62%beat
Revenue / Est. (USD)
5.20B / 5.17B
+0.60%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
5.06B
5.06B
5.29B
5.20B
Cost of goods sold
1.65B
1.54B
1.61B
1.60B
Cost of revenue
1.65B
1.54B
1.61B
1.60B
Research and development expenses
526.00M
514.00M
569.00M
516.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.72B
1.74B
1.83B
1.78B
Operating expense
2.47B
2.48B
2.63B
2.53B
Total operating expenses
4.12B
4.02B
4.24B
4.13B
Operating income
943.00M
1.05B
1.04B
1.07B
Other non operating income
440.00M
-16.00M
28.00M
28.00M
EBT including unusual items
941.00M
938.00M
700.00M
1.16B
EBT excluding unusual items
1.29B
935.00M
1.01B
999.00M
Income tax expense
146.00M
183.00M
30.00M
-176.00M
Effective tax rate
15.52%
19.51%
4.29%
-15.13%
Other operating expenses
-
-
-
-
Net income
797.00M
755.00M
672.00M
1.34B
Net profit margin
15.75%
14.91%
12.71%
25.77%
Earnings per share
0.75
0.75
0.80
0.80
Interest and investment income
-
-
29.00M
-
Interest expense
-90.00M
-87.00M
-90.00M
-90.00M
Net interest expenses
-90.00M
-87.00M
-61.00M
-90.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.28B
1.39B
1.41B
1.42B
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer